TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31183382

Group type: EXPERIMENTAL
Intervention: Traditional Karate (60 minutes twice a week for at least one year)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Traditional Karate
Number of subjects: 152
Study: 29797529

Group type: EXPERIMENTAL
Intervention: NASH subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Engaging in dedicated cardiovascular activity
Number of subjects: 40
Study: 26946333

Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT)
Number of subjects: 32810

Group type: EXPERIMENTAL
Intervention: Age >65 years
Number of subjects: 32810

Group type: EXPERIMENTAL
Intervention: Alcoholic cirrhosis
Number of subjects: 32810

Group type: EXPERIMENTAL
Intervention: Nonalcoholic steatohepatitis (NASH)
Number of subjects: 32810

Group type: EXPERIMENTAL
Intervention: Pre‐LT creatinine
Number of subjects: 32810

Group type: EXPERIMENTAL
Intervention: Baseline atrial fibrillation (AF)
Number of subjects: 32810

Group type: EXPERIMENTAL
Intervention: Stroke
Number of subjects: 32810

Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 32810
Study: 24779562

Group type: EXPERIMENTAL
Intervention: Longer duration of diabetes
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Higher fasting plasma glucose level
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c level
Number of subjects: 614
Study: 21684022

Group type: EXPERIMENTAL
Intervention: Physical therapy intervention (PTI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (pre-frail elderly women)
Number of subjects: 48
Study: 20801187

Group type: EXPERIMENTAL
Intervention: 3-month endurance training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-month strength training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone treatment in orchiectomised rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bodybuilders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetraplegic patients
Number of subjects: 0
Study: 17388762

Group type: EXPERIMENTAL
Intervention: Binaural beat at 7 Hz (30 minutes) with pink noise overlay
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control stimuli without binaural beat (30 minutes) with pink noise overlay
Number of subjects: 4
Study: 16110692

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.05 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.10 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.15 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.20 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12100776

Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib 5 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib 5 mg and 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 0
Study: 10410152

Group type: COMPARATOR
Intervention: Granisetron alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Granisetron plus methylprednisolone
Number of subjects: 27
Study: 7564369

Group type: EXPERIMENTAL
Intervention: moexipril 3.75 mg o.d.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: moexipril 7.5 mg o.d.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: moexipril 15 mg o.d.
Number of subjects: 203

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 203
Study: 2187173

Group type: EXPERIMENTAL
Intervention: Neonatal screening using IRT cutoff of 180 ng/mL
Number of subjects: 145024
Study: 6617280

Group type: EXPERIMENTAL
Intervention: heparin and hydrocortisone
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 31462121

Group type: EXPERIMENTAL
Intervention: 595 nm pulsed-dye-laser (PDL) treatment (3 treatments, 10 mm spot size, 0.45 ms, 6 J/cm2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (untreated half of the scar)
Number of subjects: 40
Study: 29402509

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AER)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RES)
Number of subjects: 30
Study: 27595918

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (weight loss)
Number of subjects: 5145

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (fitness change)
Number of subjects: 5145
Study: 24460536

Group type: EXPERIMENTAL
Intervention: Incentive-based intervention including targeted education on myopia, structured weekend outdoor activities, and incentives for increasing daily steps via pedometers.
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Incentive-based intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study: 23278322

Group type: EXPERIMENTAL
Intervention: Diflubenzuron, Eprinomectin, Fipronil, Ivermectin (feed-through treatments)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fipronil (250 p.p.m., 100 p.p.m., 50 p.p.m.)
Number of subjects: 2
Study: 19888949

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 15 mg/kg, maximum 1000 mg over 15 minutes
Number of subjects: 559

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 559
Study: 18071002

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3187

Group type: COMPARATOR
Intervention: Intensive lifestyle (ILS)
Number of subjects: 3187

Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 3187
Study: 15679783

Group type: COMPARATOR
Intervention: Non-smokers (control group)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Very heavy smokers (>30 cigarettes/day)
Number of subjects: 101
Study: 12852706

Group type: EXPERIMENTAL
Intervention: Glipizide/metformin 5/500 mg tablets
Number of subjects: 247

Group type: COMPARATOR
Intervention: Glipizide 30 mg
Number of subjects: 247

Group type: COMPARATOR
Intervention: Metformin 2000 mg
Number of subjects: 247
Study: 10587555

Group type: EXPERIMENTAL
Intervention: Sclerosing injections (dextrose-glycerine-phenol with lignocaine)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo injections (saline plus lignocaine)
Number of subjects: 74
Study: 8945675

Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide-5-mononitrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous transdermal nitroglycerin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study: 1769431

Group type: EXPERIMENTAL
Intervention: 10 mg cisapride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7329878

Group type: EXPERIMENTAL
Intervention: Commercially available medium pressure mercury sun lamps
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31564513

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg and Amlodipine 10 mg co-administration
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Co-administration of all 3 drugs
Number of subjects: 27
Study: 28142075

Group type: EXPERIMENTAL
Intervention: 20 mg/day rosuvastatin (n = 24)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 80 mg/day atorvastatin (n = 21)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (LDL‐C <3.37 mmol/L)
Number of subjects: 45
Study: 27464953

Group type: EXPERIMENTAL
Intervention: Multimodal Rehabilitation Program (MRP) consisting of graded exposure module or a combination module of graded exposure and physical training, with a parent module added. Treatment duration varies between 7 and 16 weeks.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 124
Study: 25124237

Group type: EXPERIMENTAL
Intervention: HPV vaccine (three doses)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 171
Study: 22595153

Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19678773

Group type: EXPERIMENTAL
Intervention: Verum acupuncture + 10 mg/day fluoxetine + placebo
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham acupuncture + 20‐30 mg/day fluoxetine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 18189060

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 0
Study: 15323595

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low serum folate levels
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low vitamin B12 levels
Number of subjects: 71

Group type: COMPARATOR
Intervention: Elevated homocysteine levels
Number of subjects: 71
Study: 11431189

Group type: EXPERIMENTAL
Intervention: Gabapentin (200 to 300 mg after each hemodialysis session)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9875115

Group type: EXPERIMENTAL
Intervention: MIBI‐SPECT
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Exercise stress testing
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dipyridamole echocardiography
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Echocardiographic techniques
Number of subjects: 102
Study: 7722589

Group type: EXPERIMENTAL
Intervention: Experimental group (offered the opportunity to execute an Advance Directive)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (no Advance Directive offered)
Number of subjects: 204
Study: 2783939

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2a (3 million IU to 36 million IU intramuscularly daily for 10 weeks)
Number of subjects: 22
Study: 1097480

Group type: EXPERIMENTAL
Intervention: Protriptyline 10 mg three times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perphenazine 2 mg three times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of protriptyline and perphenazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31745040

Group type: EXPERIMENTAL
Intervention: Scotchbond multi‐purpose (MP)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Single bond plus (SB)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Scotchbond SE (SE)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Easy bond (EB)
Number of subjects: 125
Study: 28592577

Group type: EXPERIMENTAL
Intervention: ASyMS intervention
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1108
Study: 25737169

Group type: COMPARATOR
Intervention: Standard triple therapy (lansoprazole, amoxicillin, and clarithromycin for 14 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Standard triple therapy plus probiotics (Lactobacillus casei, Lactobacillus acidophilus, and Bifidobacterium lactis)
Number of subjects: 61
Study: 23758279

Group type: EXPERIMENTAL
Intervention: Community-based model of care led by a general practitioner with advanced skills and an endocrinologist partnership.
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care provided via the hospital diabetes outpatient department.
Number of subjects: 330
Study: 21477426

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% nasal spray (1 spray/nostril twice-daily)
Number of subjects: 944

Group type: COMPARATOR
Intervention: Placebo (1 spray/nostril twice-daily)
Number of subjects: 944
Study: 18809153

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/day
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: atorvastatin 80 mg/day
Number of subjects: 1075

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1075
Study: 15695784

Group type: EXPERIMENTAL
Intervention: FMISO PET imaging
Number of subjects: 40
Study: 14626291

Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20 (Synvisc®)
Number of subjects: 0
Study: 10795662

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 20
Study: 8641640

Group type: EXPERIMENTAL
Intervention: Kyowa ASP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bayer ASP
Number of subjects: 40
Study: 1628635

Group type: EXPERIMENTAL
Intervention: 2% halothane in pure oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% halothane in 50% oxygen/50% nitrous oxide
Number of subjects: 0
Study: 6705617

Group type: EXPERIMENTAL
Intervention: Conversational skills training (individual coaching)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Peer involvement under superordinate goals (group experience)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Conversational skills training combined with peer involvement (group experience with coaching)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 56
Study: 31036503

Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention (diet, exercise, or diet plus exercise)
Number of subjects: 577
Study: 29315212

Group type: EXPERIMENTAL
Intervention: Higher protein intake
Number of subjects: 310
Study: 27349698

Group type: EXPERIMENTAL
Intervention: Edoxaban (higher-dose edoxaban regimen; 60 mg dose-reduced to 30 mg once daily)
Number of subjects: 14071

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14071
Study: 24940704

Group type: EXPERIMENTAL
Intervention: Knifelight carpal tunnel release
Number of subjects: 82

Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 82
Study: 22805873

Group type: EXPERIMENTAL
Intervention: Hypothermic treatment (H)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normothermic treatment (N)
Number of subjects: 50
Study: 20391147

Group type: EXPERIMENTAL
Intervention: Caloric restriction and/or resistance training
Number of subjects: 36
Study: 17907238

Group type: EXPERIMENTAL
Intervention: High‐intensity aerobic training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Qigong (control group)
Number of subjects: 80
Study: 12569112

Group type: EXPERIMENTAL
Intervention: Konjac glucomannan (KGM) supplement (3.6 g/day) for 28 days
Number of subjects: 22
Study: 10848657

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Ranitidine 300 mg b.d.
Number of subjects: 156
Study: 9139554

Group type: EXPERIMENTAL
Intervention: 200 mg of fluconazole per week
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 8229393

Group type: EXPERIMENTAL
Intervention: Tranexamic acid solution (4.8%) used as a mouthwash
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 93
Study: 3100353

Group type: EXPERIMENTAL
Intervention: Oral acyclovir 200 mg 4 times a day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30042362

Group type: EXPERIMENTAL
Intervention: Greek mountain tea 950 mg
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Greek mountain tea 475 mg
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Greek mountain tea 475 mg and 950 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Ginkgo biloba 240 mg
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 26760452

Group type: EXPERIMENTAL
Intervention: Scheduled SMS reminders (daily for 1 month, weekly for 2 months)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Triggered SMS reminders starting at enrolment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (No SMS)
Number of subjects: 63
Study: 24951991

Group type: EXPERIMENTAL
Intervention: Microencapsulated fish oil (3 g/day containing 0.41 g/day of eicosapentaenoic acid and decosahexaneoic acid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microencapsulated fish oil
Number of subjects: 30
Study: 22313884

Group type: EXPERIMENTAL
Intervention: External methods of traditional Chinese medicine (TCM)
Number of subjects: 0
Study: 20210614

Group type: COMPARATOR
Intervention: Control (CON) clothing comprising shorts, socks, and sneakers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Partial (PART) National Football League (NFL) uniform comprising the uniform without helmet or shoulder pads
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Full (FULL) NFL uniform
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Partial (PART) National Football League (NFL) uniform
Number of subjects: 10
Study: 18717873

Group type: EXPERIMENTAL
Intervention: 5% doxepin hydrochloride cream
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16404688

Group type: EXPERIMENTAL
Intervention: International therapeutic modernity and ethical rules governing experiments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New laws on international trade
Number of subjects: 0
Study: 12798825

Group type: EXPERIMENTAL
Intervention: Beta-blockers (metoprolol, bisoprolol, carvedilol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers (CIBIS II trial)
Number of subjects: 0
Study: 10230185

Group type: COMPARATOR
Intervention: Antipsychotic agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of atypical antipsychotics and psychosocial interventions
Number of subjects: 0
Study: 8781015

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1677656

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 191

Group type: COMPARATOR
Intervention: Cephradine
Number of subjects: 191
Study: 6310997

Group type: EXPERIMENTAL
Intervention: Amdinocillin plus a beta-lactam antibiotic
Number of subjects: 78

Group type: COMPARATOR
Intervention: Aminoglycoside plus a beta-lactam antibiotic
Number of subjects: 78

Group type: COMPARATOR
Intervention: Aminoglycoside
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Amdinocillin
Number of subjects: 78
Study: 31476969

Group type: EXPERIMENTAL
Intervention: Comfort provided by parents
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comfort provided by strangers
Number of subjects: 38
Study: 31277073

Group type: EXPERIMENTAL
Intervention: Targeted panel sequencing (TPS)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 125
Study: 27350625

Group type: EXPERIMENTAL
Intervention: Mirabegron (160 mg once daily) with Metformin (500 mg twice daily)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mirabegron (100 mg once daily) with Warfarin (25 mg)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mirabegron (100 mg once daily) with Digoxin (0.25 mg)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mirabegron (100 mg once daily) with COC (30/150 µg once daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Mirabegron (100 mg once daily)
Number of subjects: 111
Study: 26496210

Group type: EXPERIMENTAL
Intervention: 2 μg of paricalcitol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Treated groups (1 or 2 μg of paricalcitol)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24341367

Group type: EXPERIMENTAL
Intervention: FL‐PDT (Fractional laser-assisted photodynamic therapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FL‐PDT
Number of subjects: 40

Group type: COMPARATOR
Intervention: MAL‐PDT (Methyl aminolevulinate photodynamic therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 40
Study: 22840639

Group type: EXPERIMENTAL
Intervention: Behavioural change intervention (goal-setting, feedback, self-monitoring) delivered through individualised consultation calls and motivational SMS text messages over six months.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care (advice from doctors about physical activity).
Number of subjects: 156
Study: 19615128

Group type: EXPERIMENTAL
Intervention: Sequential non-invasive mechanical ventilation following short-term invasive mechanical ventilation
Number of subjects: 32
Study: 17719333

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1326
Study: 15533256

Group type: EXPERIMENTAL
Intervention: Inclusion of a flyer and letter with a health questionnaire informing patients that returned questionnaires would be entered into a lottery-style draw for £100 of gift vouchers.
Number of subjects: 8645

Group type: COMPARATOR
Intervention: Health questionnaire accompanied only by standard letter of explanation.
Number of subjects: 8645
Study: 11489325

Group type: EXPERIMENTAL
Intervention: Double matrix systems (starch-based hot stage extruded)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Reference immediate release formulation
Number of subjects: 9
Study: 9430568

Group type: EXPERIMENTAL
Intervention: Morphine 2 mg (Group A1)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Preoperative Morphine 2 mg (Group A2)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg (Group A3)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Preoperative Morphine 5 mg (Group A4)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 ml (Group A5)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 ml + Morphine 2 mg (Group A6)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Saline solution 20 ml (Group A7)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Morphine 5 mg (Group B2)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Preoperative Morphine 5 mg (Group B3)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 20 ml + Morphine 2 mg (Group B5)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Saline solution 20 ml (Control Group)
Number of subjects: 142